GL-0719

GL-0719 is a recombinant Fc fusion protein designed to selectively inhibit the classical and lectin (mannose-binding lectin) complement pathways, while leaving the alternative pathway intact[1][5]. This targeted inhibition is achieved through high-affinity binding to complement C1q, which prevents activation of downstream components involved in cell destruction and inflammation[4]. Unlike monoclonal antibodies, its mechanism may allow for lower dosing. In addition to blocking two key complement pathways, GL-0719 increases anti-inflammatory blood factors. Preclinical studies have shown efficacy in animal models of diseases driven by aberrant complement activation, including acute intravascular hemolysis, glomerulonephritis, and nephritis[1]. The drug is being developed primarily for complement-mediated diseases such as cold agglutinin disease (CAD), with potential applications across hematologic, neurologic, and renal indications[7][6].